Skip to main content
OpenTrials
Completed

NCT Number: NCT02275208

A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure

This study is a prospective, multi-center, single-arm study evaluating the SIPS procedure. Subjects who meet the eligibility criteria will be considered for study participation and will be followed through 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Parker, Colorado, United States

Loading trial locations.

About this study

SIPS is a single-anastomosis duodeno-intestinal switch procedure. Preliminary data from Sanchez-Pernaute et al. (Surg Obes Relat Dis 2013;9:731) indicates that this procedure is safe, quick to perform, and offers good results for treatment of both morbid obesity and its metabolic comorbidities. CovidienTM plans to further investigate this procedure and has proposed a prospective clinical study to obtain data on subject outcomes through 12 months following the SIPS procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject must be 18-65 years of age
  • The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent
  • The subject is under consideration for surgery for obesity or metabolic disease and elects to undergo a primary SIPS procedure
  • The subject has a BMI of 35-40 kg/m2 with at least 1 obesity-related comorbidity or a BMI of 40-60 kg/m2

Exclusion criteria

  • Any female subject who is pregnant, or is actively breast-feeding
  • Any subject who is considered to be part of a vulnerable population (e.g. prisoners or those with psychological concerns or those without sufficient mental capacity)
  • The procedure is an emergency procedure
  • The procedure is a revision/reoperation for the same indication
  • The subject is unable or unwilling to comply with the study requirements or follow-up schedule
  • The subject has conditions which, in the opinion of the investigator, will not be appropriate for the study (e.g. severe cardiovascular disease, history of gastrointestinal (GI) malignancy, history of upper GI surgery, open cholecystectomy, history of intestinal surgery, immunosuppression, or non-ambulatory)
  • The subject has an estimated life expectancy of less than 6 months
  • The subject has participated in an investigational drug or device research study within 30 days of enrollment

Treatment and study plan

SIPS the stomach, intestinal, pylorus, sparing procedure

Procedure

Bariatric Procedure

Primary outcomes

  1. The primary endpoint is excess weight loss (EWL) at 12 months.

    Time frame: 12 months

Secondary outcomes

  1. SIPS-related adverse events at all timepoints

    Time frame: 12 months

  2. Resolution of comorbidities at 1, 6, and 12 months

    Time frame: 12 months

  3. Quality of life (QOL) (SF-36 and gastroesophageal reflux disease - health related quality of life [GERD-HRQL]) at 6 and 12 months

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Medtronic - MITG

Industry

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Oct 27, 2014
Registry last updated
May 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.